Newsroom

The Ivy Brain Tumor Center has announced initial results from an ongoing, dual-drug Phase 0 study evaluating the tumor pharmacokinetics (PK) and tumor pharmacodynamics (PD) of abemaciclib, a selective CDK4/6-inhibitor, plus LY3214996, a selective ERK1/2 inhibitor, in recurrent glioblastoma patients.

Warrington mother of two Louise Hulme, who flew to America for life-saving surgery to remove a stage four brain tumor, is now preparing for phase two of her journey.

Last year, while serving on the frontlines against COVID-19, Ian Youngblood was diagnosed with glioblastoma. Now, Ian is back in Arizona and doing what he loves which includes teaching yoga classes, hiking and motivating everyone around him. On Saturday, May 29, Ian led a charity class in Scottsdale, AZ to support the cutting-edge research happening at the Ivy Brain Tumor Center.

Just five weeks after his fourth child was born, Tim Jackson, a 43-year-old nurse from Arizona, was diagnosed with brain cancer. Tim and his wife, Amber, remain optimistic as he participates in a new Ivy Phase 0 clinical trial for newly diagnosed glioblastoma.

Louise and her husband Kev continue to manifest hope and overcome challenges in the face of a glioblastoma diagnosis. Traveling from the United Kingdom to the United States to participate in an Ivy Phase 0 clinical trial, Louise is determined to fight like a true brain tumor warrior.

Governor Doug Ducey declared May to be Brain Tumor Awareness Month to promote education of the condition, recognize the medical professionals who combat the issue, highlight the significant progress in research, and honor the families who have been impacted.

In the latest edition of CURE magazine's Clinical Trial Corner, the Ivy Center's first-in-human clinical trial of noninvasive sonodynamic therapy for recurrent brain cancer was highlighted.

The Ivy Center is pleased to announce the dosing of its first patient in a first-in-human Phase 0 clinical trial of sonodynamic therapy, a noninvasive drug-device combination developed by SonALAsense in collaboration with Insightec. This historic study aims to develop a nonsurgical treatment option for patients with recurrent glioblastoma and other high-grade gliomas.

In this Techonomy exclusive from Dr. Nader Sanai, director of the Ivy Brain Tumor Center, he discusses the "fail fast" adage associated with Silicon Valley and the implications this method could have on the healthcare industry specifically, in clinical trials.

The Ivy Brain Tumor Center at Barrow Neurological Institute has announced the first patient has been treated in a Phase 0 clinical trial of pamiparib in newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM). This is the first Phase 0 clinical trial open to newly diagnosed glioblastoma patients.